Table 5.

Factors affecting the decision to prescribe tamoxifen for patient (% agreement, n = 928)

	Willingness to prescribe
	Overall, %	Unwilling, %	Willing, %	P-value
	Evidence for the benefits of the drug	95.0	87.6	97.2	<0.001
The existence of NICE guideline (or national equivalent)	95.0	87.6	97.2	<0.001
Patient awareness of possible harms and benefits	94.1	81.9	97.6	<0.001
The patient’s level of risk for breast cancer	93.8	82.9	96.9	<0.001
Patient interest in taking tamoxifen	90.6	74.8	95.3	<0.001
GPs’ confidence in their knowledge of tamoxifen	89.5	83.3	91.4	0.001
Evidence for the harms of the drug	89.3	89.0	89.4	0.880
The patient’s support from the family history clinician^a	88.6	69.0	94.3	<0.001
First prescription being made by family history clinician	86.0	72.7	88.4	<0.001
Policy of GPs’ clinical commissioning group	80.2	82.4	79.5	0.360
Prescribing off-label	74.6	91.4	69.6	<0.001
The first prescription being made by GP	71.9	85.0	66.0	<0.001
Attitudes of colleagues at the same career stage	61.6	57.6	32.8	0.170
Attitudes of more senior colleagues	59.4	58.1	59.7	0.670
Prescribing budget in GPs’ general practice	42.1	41.4	42.3	0.810
Financial costs of tamoxifen	41.4	37.6	42.5	0.210

↵a This item was only asked of those GPs allocated to the relevant condition. NICE = National Institute for Health and Care Excellence.